Objective: Neck and thorax single photon emission computed tomography with computed tomography (SPECT-CT) improves the reliability of postablation 131 I whole-body scan (WBS) for differentiated thyroid cancer (DTC). The aim of this study was to assess the prognostic value for persistent or recurrent disease of postablation 131 I scintigraphy combining WBS and neck and thorax SPECT-CT with that of the previously known predictive factors. Methods: This is a single referral center prospective study with a median follow-up of 29 months. Postablation 131 I WBS and neck and thorax SPECT-CT were performed in 170 consecutive patients treated between 2006 and 2008. Stimulated serum thyroglobulin (Tg) and anti-thyroglobulin antibodies (TgAb) levels were measured. The impact on disease-free survival of age; gender; postablation 131 I scintigraphy; stimulated serum Tg level; T, N, and M status; and macroscopic lymph node involvement was assessed by univariate and multivariate analyses. Results: Persistent or recurrent disease was observed in 32 (19%) patients. In the whole group of patients, only positive WBS with SPECT-CT was related to an increased risk of persistent or recurrent disease (hazards ratio (HR)Z65.21, 95% confidence interval (CI)Z26.03-163.39, P!0.0001). In patients without TgAb (nZ146), both positive WBS with SPECT-CT (HRZ18.86, 95% CIZ5.02-70.85, P!0.0001) and serum Tg level R58 ng/ml (HRZ4.42, 95% CIZ1.18-16.53, PZ0.0271) were associated with an increased risk. Conclusion: In patients with DTC, the cross analysis of postablation 131 I scintigraphy with neck and thorax SPECT-CT and stimulated serum Tg level enables early assessment of the risk of persistent or recurrent disease.
Introduction
Persistent or recurrent disease in lymph nodes or in the thyroid bed occurs in w5-25% of patients with differentiated thyroid cancer (DTC) depending on the selection of patient, and distant metastases are observed in about 5% of cases. In clinical practice, there is a need for early identification of patients with residual disease and those at a risk of developing such recurrences. At present, the risk assessment is based on the AJCC/UICC pTNM classification (1) , initially developed to predict risk for death. A three-level stratification for the assessment of risk for recurrence was also recently proposed by the American Thyroid Association (ATA) considering other variables such as histological subtype, results of postablation 131 I scintigraphy, or possibly thyroglobulin (Tg) level (2) .
Recently, we and others have shown that routine neck and thorax single photon emission computed tomography with computed tomography (SPECT-CT) greatly improves the interpretation of postablation 131 I whole-body scan (WBS) owing to the direct correlation between functional and anatomical imaging (3, 4) . In accordance with previous studies (5) (6) (7) , we also reported, though on a limited number of patients, that persistent/recurrent disease was associated with high, stimulated serum Tg level at ablation (O30 ng/ml) and with initial macroscopic lymph node involvement (3) .
The aim of this study was to assess the prognostic value for persistent or recurrent disease of postablation 131 I scintigraphy combining WBS and neck and thorax SPECT-CT with that of previously known clinical, biological, and pathological predictive factors.
Materials and methods

Patients
The study group included 170 consecutive patients with DTC who underwent radioiodine ablation from January 2006 to December 2008 (Table 1 ). Of these, 55 patients, treated in 2006, were part of a previous report (3) . Diagnosis of DTC was based on the written pathological report.
Radioiodine ablation and postablation 131 I scintigraphy
Radioiodine ablation treatment was given at a median interval of 10 (range 4-58) weeks after surgery, either after withdrawal of thyroid hormone treatment or after two injections of recombinant TSH (rhTSH) (Thyrogen, Genzyme Corp., Cambridge, MA, USA). Serum TSH, Tg, and anti-thyroglobulin antibodies (TgAb) were measured immediately before administration of radioiodine.
Postablation 131 I scintigraphy was performed using a double-head gamma camera equipped with 1.5875 cm (5/8 in) NaI crystals and a multidetector (two rows) spiral CT (Symbia T2, Siemens Medical Solutions, Malvern, PA, USA) as described previously (3) . Each patient had a postablation 131 I scan combining WBS and SPECT-CT acquisitions of the neck and thorax. Of the total patients, four patients also had SPECT-CT on the abdomen and pelvis due to dubious foci on WBS. Postablation 131 I scan was performed 5 (nZ151), 4 (nZ7), or 2 (nZ12) days after treatment. It was interpreted by two experienced nuclear medicine physicians (N A, S B) and a head and neck surgeon (J P R) for the first previously reported 55 patients and by at least one nuclear medicine physician (N A or/and S B) for the remaining 115 patients. The final conclusion was based on the analysis of SPECT-CT for neck and thorax. Other than neck and thorax, the conclusion was based on WBS except when SPECT-CT was available. Each focus of 131 I uptake was scored negative (benign), positive (malignant), or indeterminate according to the definitions reported by Aide et al. (3) . At patient level, postablation 131 I scan was scored negative (benign) when all foci were negative, positive (malignant) when at least one focus was positive, or indeterminate when at least one focus was considered indeterminate without any positive foci.
Tg and TgAb evaluation
Serum Tg and TgAb measurements were simultaneously performed. From January 2006 to May 2008, serum Tg was measured using the immunometric assay , CT of the neck and thorax, or FDG-PET were performed. Persistent or recurrent disease was defined as evidence of tumor in the thyroid bed, lymph node metastases, or distant metastases after completion of initial treatment (surgery and radioiodine ablation). Confirmation was obtained either by histology or by complementary imaging modalities and follow-up. Otherwise, patients were considered disease free.
Data analysis
Patient characteristics were compared using Fisher's exact test or the Kruskal-Wallis test as appropriate. Time to persistent or recurrent disease was calculated from the day of postablation 131 I scintigraphy to the date of diagnosis of persistent or recurrent disease, or August 1st 2010, whichever came first. Date of diagnosis was either date of biopsy or surgery, or that of positive imaging modalities, or that of postablation 131 I scintigraphy when persistent tumor was shown only on scintigraphy. In this latter case, time to persistent disease was arbitrarily defined as 1 month. The Kaplan-Meier method was used to estimate the probability of survival. The following variables were analyzed: age at diagnosis (!45 vs R45 years); gender; postablation 131 I WBS with SPECT-CT (negative or indeterminate versus positive); serum Tg level at ablation (!58 vs R58 ng/ml) in patients with or without TgAb; T3 or T4 vs T1 or T2), N (N1a or N1b vs N0 or Nx), and M status according to the 2002 TNM classification; and macroscopic lymph node involvement (N1 macroscopic versus N1 microscopic or N0 or Nx) as described previously (7) . The 58 ng/ml cutoff for serum Tg level was obtained by multiplying the previously reported threshold of 30 ng/ml (3, 5) by 1.92 as described earlier for comparison with CRM-457-calibrated assays. The estimates in each group were compared using the log-rank test (univariate analysis). An analysis of prognostic factors was performed using the multivariate Cox regression model with a stepwise selection. Statistical significance was defined as P!0.05. All tests were two sided. SAS 9.2 statistical software (SAS Institute, Cary, NC, USA) was used to analyze the data. Table 1 reports the clinical and pathological features of the 170 patients using the pTNM classification.
Results
Patient characteristics
Radioiodine treatment was given after withdrawal of thyroid hormone treatment (nZ133) or after rhTSH (nZ37) with a mean activity of 3752 MBq (range 925-4810). All TSH values at time of radioiodine administration were above 30 mU/l. Overall, the median follow-up was 29 months (range 8-54).
Of the 170 patients, 32 (19%) showed persistent or recurrent disease up to 44 months after postablation 131 I scintigraphy (Tables 1 and 2 ). All but one had radioiodine ablation after withdrawal of thyroid hormones. Eighteen patients had persistent or recurrent disease in the neck only, eight patients showed distant metastases (lung and/or bone) only, and six patients exhibited both neck tumor and distant metastases. At the time of last visit, 21 (66%) of these patients were considered disease free.
Postablation scintigraphy
Postablation scintigraphy in the 32 patients with persistent or recurrent disease was considered positive in 25 (78%) and negative in the remaining seven patients (22%). It was negative or indeterminate in all 138 (100%) patients who remained disease free. As a result, sensitivity and specificity for postablation scintigraphy were estimated at 78 (95% confidence interval (CI): 60-91%) and 100% respectively.
SPECT-CT clearly demonstrated isolated, lymph node involvement in 12 patients (patients 3, 6, 9, 11-14, 16, Table 2 Patients with persistent or recurrent disease. (patients 3, 6, 12-14, 18 , 20, and 24) including radioiodine-guided dissection for seven patients, and all were disease free at last visit; and the remaining four (patients 9, 11, 16, and 29) were treated by radioiodine of who two developed second recurrence in lungs. At last follow-up, two of these four patients were disease free. SPECT-CT also showed neck lymph node involvement associated with lung metastases in four patients (patients 7, 10, 19, and 31). Patient 19 with central and lateral nodal persistent disease and lung foci, without nodules on integrated CT, was disease free after both surgery and a 5.9 GBq cumulative activity of radioiodine.
WBS with SPECT-CT depicted iodine-avid distant metastases in nine patients: lung metastases in five patients (patients 8, 15, 26, 27, and 32), bone metastases in two patients (patients 22 and 28), both lung and bone metastases in one patient (patient 25), and bone metastases with neck residual disease in one patient (patient 23).
Of these 25 positive results, postablation scintigraphy detected previously unknown distant metastases in ten patients (patients 7, 8, 10, 15, 19, 22, 26-28, and 31). For seven of them, conventional imaging remained negative. In patients 22 and 28, WBS and SPECT-CT revealed bone uptake without lesions on integrated CT. Bone scan, MRI, and PET were also negative. Complete remission, i.e. disappearance of bone uptake and undetectable stimulated Tg level, was obtained after one or three radioiodine treatments. Similarly, four patients (patients 15, 19, 26, and 27) with lung uptake and normal integrated CT were cured after two radioiodine treatments.
Among the seven patients with a negative postablation scintigraphy, one (patient 1) had persistent tracheal invasion, one (patient 2) showed lung metastases and neck nodal disease, and five (patients 4, 5, 17, 21, and 30) exhibited neck nodal disease only. In all these iodine non-avid patients, persistent/recurrent disease was demonstrated by US and/or FDG-PET. In three patients, residual tumor was also suspected on the integrated CT of hybrid equipment. All seven patients but one had stimulated Tg level above 58 ng/ml. Patient 4 with Tg level at 39 ng/ml showed the latest nodal recurrence at 44 months.
Stimulated serum Tg
Serum TgAb was present in 24 (14%) patients. In the whole group of patients (nZ170), stimulated serum Tg at ablation was higher in patients with persistent or recurrent disease (median: 110 ng/ml, range 0.1-61018) than in patients in complete remission (2 ng/ml, 0.1-94; P!0.0001). Similar, results were observed in patients without serum TgAb (nZ146), i.e. 131 ng/ml (4-61018, nZ28) vs 2 ng/ml (0.1-94, nZ118) respectively (P!0.0001). A receiver operating characteristics (ROC) study confirmed that the optimal cutoff for stimulated serum Tg to predict persistent or recurrent disease was 58 ng/ml (Fig. 1 ). In the whole group of patients, the sensitivity and specificity for that cutoff were 66 (95% CI: 58-73%) and 98% (95% CI: 94-99%) respectively. The figures in patients without serum TgAb were 71 (95% CI: 63-79%) and 98% (95% CI: 95-100%).
In the whole group of patients, three with stimulated serum Tg R58 ng/ml did not develop persistent or recurrent disease as defined in this study. Of the three patients, one had large pretracheal thyroid remnants well demonstrated on postablation scintigraphy and on US. The rhTSH-stimulated Tg at 9 months was undetectable, with negative 185 MBq 131 I scintigraphy and neck US. The remaining two patients received a second radioiodine treatment 8 and 12 months later respectively. Serum Tg levels after hormone withdrawal was 52 and 14 ng/ml with still a negative posttherapeutic scintigraphy. Neck US, thoracic CT san, bone scan, and PET were also negative in both the patients.
Conversely, 11 patients (patients 4, 9, 11, 15, 16, 18, 20, 22, 26, 27 , and 28) with stimulated serum Tg !58 ng/ml, of whom three had serum TgAb, showed persistent/recurrent disease. All but one had a positive postablation scintigraphy consistent with persistent disease in the neck (nZ5) or with distant metastases (nZ5). The remaining one patient (patient 4 already described) presented a late nodal recurrence. Complete remission was obtained after radioiodine treatment and/or surgery in all but one patient.
The data also show that, in patients without persistent or recurrent disease, stimulated serum Tg was higher after withdrawal of thyroid hormones (3 ng/ml, 0.1-86, nZ102) than after rhTSH (0.6 ng/ml, 0.1-94, nZ36; PZ0.004).
Prognostic analysis
In the whole group of patients (nZ170), six variables were significantly associated with disease-free survival by univariate analysis: T, N, and M status according to the 2002 TNM classification, macroscopic lymph node involvement, serum Tg level at ablation and WBS with SPECT-CT (P!0.0001 for each variable; Fig. 2 ). Gender and age at diagnosis were not significantly associated with disease-free survival (PZ0.0564 and PZ0.7618 respectively). All these variables were then included in a multivariate Cox regression model except age. Only positive WBS with SPECT-CT (HRZ65.21, 95% CIZ26.03-163.39, P!0.0001) was associated with an increased risk of persistent or recurrent disease (Table 3) .
When only patients without serum TgAb (nZ146) were considered, both positive WBS with SPECT-CT (HRZ18.86, 95% CIZ5.02-70.85, P!0.0001) and serum Tg level at ablation R58 ng/ml (HRZ4.42, 95% CIZ1.18-16.53, PZ0.0271) were related to an increased risk by multivariate analysis. The corresponding 24-month disease-free survival was 100% in patients with negative or indeterminate postablation scintigraphy and Tg level !58 ng/ml, 25% (95% CI, 4-56%) in patients with negative or indeterminate scintigraphy and Tg level R58 ng/ml, 14% (95% CI, 1-46%) in patients with positive scintigraphy and Tg level !58 ng/ml, and 7% (95% CI, 1-27%) in positive scintigraphy and Tg level R58 ng/ml ( Fig. 3 ; P!0.0001).
Discussion
Planar 131 I scintigraphy is known to be associated with a substantial number of equivocal results, or even false positives (8) . In recent years, it has been shown that the analysis of SPECT-CT images helps to precisely localize focal iodine uptake and to characterize it as either normal or abnormal. In postablation setting, neck and thorax SPECT-CT improves the N staging of patients with DTC (4, 9) . SPECT-CT data may also reduce the need for additional cross-sectional imaging in 20% of patients and alter the ATA risk of recurrence classification in 6% of patients (10) . In a primary report, we demonstrated that a positive postablation SPECT-CT predicted treatment failure at 2 years better than a positive WBS (3). Because of a limited number of patients and lack of statistical power, the prognostic value of postablation scintigraphy with SPECT-CT could not be assessed in that study in comparison with that of known prognostic factors. In this study, including 170 consecutive and unselected patients with a median follow-up of 29 months, postablation scintigraphy was shown to be the sole independent prognostic variable for disease-free survival. Combining WBS and SPECT-CT enabled to identify previously unknown distant metastases in ten patients. Interestingly, conventional imaging, including integrated CT, remained negative in seven patients, stimulated serum Tg level was below 58 ng/ml in five patients, and six patients with lung or bone uptake were considered disease free after one to three radioiodine treatments. This strongly suggests that most of these patients presented with distant micrometastases and emphasizes both the diagnostic and the therapeutic role of radioiodine ablation in such patients. SPECT-CT also clearly showed isolated, persistent lymph node disease in 12 patients and allowed an experienced surgeon to plan reoperation with confidence, i.e. radioguided surgery a few days after a second therapeutic activity of radioiodine as previously reported (11) . Complete remission could be safely achieved in all operated patients providing better results than those recently reported (12) . Half of the patients treated by radioiodine only also achieved complete remission, suggesting that this treatment can also be effective in that setting, at least in smallvolume tumors as recently published (13) . Although highly sensitive, post-ablative scintigraphy was negative in w20% of patients who had persistent/recurrent disease. In most of these patients, however, high stimulated Tg levels led to other imaging modalities, i.e. neck US, thorax CT scan, and FDG-PET, which detected iodine non-avid persistent disease. In one patient (patient 4), who showed the latest recurrence, stimulated Tg level below 58 ng/ml was most likely related to a small tumor burden that progressively increased until detectable. As previously reported (3, 4) , the main advantage of SPECT-CT is to accurately localize iodine foci and clearly characterize them as normal or abnormal. This allows nuclear medicine physicians to interpret scintigraphy with confidence and with an improved specificity. High stimulated serum Tg level at ablation (R58 ng/ml) was also shown as an independent prognostic factor for disease-free survival in the subgroup of patients where its measurement is known to be entirely reliable, i.e. in patients with no TgAb (14) . This subgroup of patients represented 86% of the whole cohort, the proportion of TgAb being consistent with that of the earlier reports (15, 16) . Few studies have focused on the prognostic value of stimulated Tg at ablation (5, 6, 16) . In a retrospective study of 212 patients with no TgAb and a 5-year follow-up, Toubeau et al. (5) showed that a serum Tg level O30 ng/ml and the presence of node invasion were predictive of disease progression. In another retrospective study of patients treated between 1986 and 2000, Heemstra et al. (16) reported that a similar stimulated serum Tg level cutoff at 27.5 ng/ml was found as an independent prognostic factor for disease-free survival with a sensitivity of 84% and a specificity of 89%. In the study by Kim et al. (6) 35 of the 268 patients (13%) showed recurrence during a mean 5-year follow-up. Of the 35 patients, 23 (66%) had stimulated serum Tg level O29 ng/ml. In a preliminary attempt to determine which group of patients might particularly benefit from SPECT-CT, we also found that a 30 ng/ml threshold might be appropriate (3) . Therefore, in this study, we conducted the statistical analysis using this cutoff which actually corresponded to 58 ng/ml after multiplication by the 1.92 CRM-457-calibration factor. ROC analyses a posteriori validated this cutoff as the optimal one in our cohort, providing the best sensitivity and specificity. Is this cutoff as appropriate in patients treated after hormone withdrawal as in patients treated after rhTSH? This issue cannot be resolved in this study because of a limited number of patients treated by rhTSH and the occurrence of only one event in such patients. However, the observation in patients who remained disease free that stimulated serum Tg was significantly higher after hormone withdrawal than after rhTSH, suggests that the Tg cutoff might be not equivalent in each group.
At ablation, stimulated serum Tg level is likely to be correlated with the volume of normal thyroid remnants, and if present, with the burden of the residual tumor. As discussed earlier, stimulated Tg 'false negatives' were mostly observed in patients with micrometastases evidenced by postablation scintigraphy only and were successfully treated by radioiodine. Although not found in the present cohort, poorly differentiated histological subtypes might also be associated with false negatives, not only for Tg but also for postablation scintigraphy. Conversely, stimulated Tg 'false positives' can be related to large thyroid remnants as we observed in one patient. Finally, two other Tg false positives would not have been observed if patients with isolated detectable Tg level were also considered as having persistent or recurrent disease. This suggests that the definition of persistent/ recurrent disease, which can vary from one study to another, may also be critical for data analysis.
Recent reports suggest that, both in low-risk (17) and in intermediate/high-risk subjects (18) , the risk stratification can be refined by ongoing assessment within the first 2 years. Our data demonstrate that an accurate risk assessment can be achieved very early, at ablation, using postablation scintigraphy with SPECT-CT and stimulated Tg level. Each of these tools enables to identify patients at high or low risk of residual or recurrent tumor with good sensitivity and specificity. The cross analysis of both variables further improves the categorization of patients. Those combining negative postablation scintigraphy and low stimulated serum Tg level clearly show a very limited risk of persistent/ recurrent disease. On the contrary, owing to an excellent specificity, positive postablation scintigraphy is related to a high risk of residual tumor, whatever serum Tg level and TgAb status. Finally, when postablation scintigraphy is negative, the simultaneous finding of a high stimulated serum Tg level enables to target patients with w30% risk of presenting persistent/ recurrent disease.
Conclusion
These data provide evidence for a new risk stratification system dedicated to persistent/recurrent disease. This system would be based on the analysis of 131 I postablation scintigraphy combining WBS and neck-thorax SPECT-CT and of stimulated Tg level. These imaging modalities and biological assays, now available in routine practice, would optimize the management of most patients with DTC.
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